Georgia Cancer Center

Last week, @ZhuPeipei presented her research on neutrophils during a Research in Progress presentation hosted by the @GACancerCenter. Neutrophils comprise more than 60% of white blood cells that repair the body from infection and help heal tissue. #research #immunology

Augusta University’s undergraduate neuroscience program celebrated a major milestone this semester by graduating its first cohort of students. Since launching three years ago, the program has grown from 16 students to more than 100. jagwire.augusta.edu/neuroscience-p…

The latest PaceDay fundraising campaign raised $366,217 for cancer research at @GACancerCenter, with a total of $2 million donated since 2019. Read more, with an exclusive interview with @jorgecortesmd. ➡️ buff.ly/HjwbtVd

Rectal spacers in prostate radiotherapy: Balancing efficacy, safety, and patient experience. Michael Greenberg, MD @JeffersonUniv & @DanWelchons @AMPofNY join @zklaassen_md @GACancerCenter to discuss rectal spacing before #ProstateCancer radiotherapy. They trace the product evolution from SpaceOAR's pegylated hydrogel to Barrigel®. #WatchNow on UroToday > bit.ly/4cfWBs6 @Barrigel_spacer @teleflex

CORE-008 cohort B investigates cretostimogene grenadenorepvec for BCG-exposed high-risk #NMIBC. @tbivala1 @PennMedicine discusses with @zklaassen_md @GACancerCenter explaining that cretostimogene is an oncolytic immunotherapy with dual mechanism through viral replication causing tumor lysis and GM-CSF encoding that stimulates immune response. #WatchNow on UroToday > bit.ly/4rOssGo #SUO24 @cgoncology

What role does quality of life play in the management of metastatic hormone-sensitive prostate cancer? Presentation by @DrYukselUrun @AnkaraUni. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4w20l8r @APCCC_Lugano

Rectal spacers in prostate radiotherapy: Balancing efficacy, safety, and patient experience. Michael Greenberg, MD @JeffersonUniv & @DanWelchons @AMPofNY join @zklaassen_md @GACancerCenter to discuss rectal spacing before #ProstateCancer radiotherapy. They trace the product evolution from SpaceOAR's pegylated hydrogel to Barrigel®. #WatchNow on UroToday > bit.ly/4cfWBs6 @Barrigel_spacer @teleflex

Congratulations to @adil__rasheed for earning the  "Biomedicines" Young Investigator Award. Dr. Rasheed's research is focused on the intersection of lipid metabolism with immune cell fate and function in atherosclerotic cardiovascular disease. 📰 - bit.ly/4tttV5h

Top Cancer Institutes on 𝕏 during Q1 2026, based on oncologists' posts and views. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials | @aiims_newdelhi | @DanaFarber | @MSKCancerCenter | @NHSBartsHealth | @UTMDAnderson | @WmsCInstitute | @UCSDCancer | @MayoClinic | @AnkaraUni_en | @PeterMacCC | @Georgetown | @incanMX | @pmcancercentre | @fortis_hospital | @cityofhope | @NorthwellHealth | @ClevelandClinic | @UTSWMedCenter | @GustaveRoussy | @UHhospitals | @StadtpolizeiZH | @GACancerCenter | @KartalSehir | @aun_edu_eg | @SanRaffaeleMI | @DrRishabhOnco | @PTarantinoMD | @HHorinouchi | @CentralParkWMD | @tompowles1 | @UroDocAsh | @jasonwilliamsmd | @dr_yakupergun | @TylerSbrt7 | @VincentRK | @DrYukselUrun | @DrMHofman | @StephenVLiu | @jryckman3 | @DraMartinezLago | @OscarTahuahua | @ArndtVogel | @SuyogCancer | @hoperugo | @kazuki_nozawa | @GIMedOnc

Colorectal cancer is rising in adults under 50. Augusta University research highlights disparities in diagnosis, treatment delays and survival, emphasizing the need for earlier detection and equitable care. jagwire.augusta.edu/young-adults-w…

We are excited to have such a strong representation at Immunology 2026 hosted by the American Association of Immunologists in Boston this week. Here is a quick snapshot of where IMMCG researchers and trainees will be throughout the week.

Real-world experience with the Expanded Access Program for 89Zr-girentuximab PET in small renal masses. R. Jonathan Henderson, MD @ArUrology, joins @zklaassen_md @GACancerCenter to share insights from implementing this technology in his high-volume Arkansas practice, noting that the #ZIRCON trial demonstrated approximately 90% sensitivity and specificity for identifying clear cell renal cell carcinoma. #WatchNow > bit.ly/4iqk0bW

⚛️ Long-term patient goals are essential to initial TKI selection within an evolving CML treatment paradigm according to @jorgecortesmd of @GACancerCenter. Read more here 🔬: hubs.li/Q048Mj170 #leusm #oncology

Last week, Kathy Li presented during our weekly Research In Progress series. Kathy is an MD/PhD student with @MCG_AUG and the Molecular Oncology and Immunology Program. She works in both the Liu and Kaplan labs and is a part of the NIH-AU Graduate Partnership Program.

Board-certified urologist, Dr. Ashanda Esdaille is now also board-certified in Lifestyle Medicine and starts a new urologic cancer survivorship clinic next month. @GACancerCenter

Catherine “Lynn” Hedrick, PhD, co-director of Augusta University’s Immunology Center of Georgia, has been appointed to the Board of Directors of the Southeastern Immunology Symposium and the Georgia Research Alliance Board of Trustees. Read more: jagwire.augusta.edu/hedrick-named-…

Identifying the Right Patient for [⁸⁹Zr]Zr-Girentuximab PET–CT Imaging in Clear Cell #RCC. @zklaassen_md @GACancerCenter & Vitaly Margulis, MD @UTSWMedCenter discuss the emerging role of Girentuximab PET-CT in #KidneyCancer. With >85% sensitivity/specificity (ZIRCON trial), it offers a “non-invasive, image-based biopsy” for select cases—useful in staging and guiding multimodal care. #WatchNow > bit.ly/46IFsof

The Gold Humanism Honor Society recognizes physicians who exemplify compassionate, patient-centered care and serve as role models for humanism in medicine. Priyanka Raval was selected for this recognition due to her outstanding dedication to both her patients and the community.

Moving beyond TURBT: Durable LG-IR #NMIBC control with primary chemoablation. @SPINCHS @AtlanticHealth and @zklaassen_md @GACancerCenter discuss long-term outcomes from the #ENVISION trial evaluating mitomycin (ZUSDURI™) for low-grade intermediate-risk nonmuscle-invasive #BladderCancer. #WatchNow on UroToday > bit.ly/3X48RUj @UroGenPharma

Cohort P data from the BOND-003 study in BCG-unresponsive papillary #BladderCancer. @MarkTysonMD @MayoClinic joins @zklaassen_md @GACancerCenter in this discussion on UroToday. At median six-month follow-up, high-grade recurrence-free survival reached 95.7% at three months, 84.6% at six months, and 80.4% at nine months. #WatchNow on UroToday > bit.ly/4pTE4WH